Industry Briefs: December 10, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
Amorfix Life Sciences has established a collaboration with CNJ Holdings, a wholly owned subsidiary of Cangene, for the identification and development of therapeutic antibodies against proprietary disease specific epitopes identified using Amorfix’s ProMIS discovery technology for treating various oncology indications.
AMRI has extended its commercial supply relationship with GE Healthcare for aminobisamide hydrochloride.
Impact Analytical announced an expansion that includes new testing and analysis laboratories. The project is scheduled to be completed by March 2013.
Kemwell has signed an agreement with Mercury Pharma for the manufacturing of pharmaceuticals at its new production facility in Uppsala, Sweden.
Sartorius Stedim Biotech has launched its Sartoguard NF prefilter series, featuring a combination of high-performance polyethersulfone membranes and nanofleece technology.
People News
AAIPharma has appointed Timothy Rhines as senior director of biopharmaceutical Development.
In addition, AAIPharma has also appointed David Browne director of analytical chemistry.
AmerisourceBergen has named Peyton R. Howell senior vice-president of AmerisourceBergen Corporation, and president of global sourcing and manufacturer relationships.
Pfizer has elected CEO Ian Read as chairman of the board.
Roche has announced several changes to its board of directors, and has proposed CEO Severin Schwan as a new member of the board.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
